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Abstract: This study included Iourty chronic renal
failure patients aged 37 - 83 years (mean 51.3±7) on
thrice weekly I-IDx for 4 - 144 month (KtN> 1.2).
Acetate dialysate with Calcium concentration of 3
mEq/L was used. All phosphate binders were
discontinued for one month.
Patients were divided in two groups. Group I (20
cases) received CA, while group II ('lO cases)
received CC in cquimolar dose (10 m.mol, of either
t.i.d.) for one month. Crossover of rrcauncnt was done
for another month while keeping paticm-. on the same
diet.
Serum levels of total calcium (Ca), ionized Ca (iCa),
phosphorus (P), alkaline phosphates (AP), urea (U).
creatinine (Cr), ALT, AST, total proteins CTP) and
albumin (Alb) were estimated before, and at the end
of each month of CA and CC treatment.
serurn Ca and iCa were significantly lower in group I
after CA compared to values after CC (p<o.n I).
Similar results in Ca levels were observed in group II
(P<0.05).
In group II only serurn I' was significantly lower after
CA compared to its values after CC (1'<0.05).
There was no signilïcant difference in AI', U, Cr,
ALT, AST, TI' and Alb before, and at the end of each
month of CA and CC treatment (1'>0.05 in ail). We
excluded 12.Yk of cases due to CA intolerance while
non of cases had similar intolerance to Cc.
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Conclusion
I) CA is not very superior to CC in control of
hyperphospbataernia.
2) CA can be safely increased without the risk of
hypercalcemia.
3) Active Vitamin D and high dialysate Ca can be
used to suppress parathyroid activity more
safely with CA than with Cc.
-l ) Tolerability to CC is superior.
Introduction
l lypcrphosphatemia plays a major role in renal
osteodystrophy 19J. The management of
hypcrphosphatcmia is rather difficult as poor
phosphate diet may interfere with adequate
nutrition of chronic renal failure patients.
Moreover, phosphate binders have many
drawbach 1161. The first phosphate binder used
was aluminium hydroxide. Constipation is common
and more seriously aluminium intoxication in
uremic patients receiving this compound for a long
time 126, 231. Calcium carbonate was thus
introduced to replace aluminium compounds. It
causes heart burn, constipation beside the risk of
hypercalcemia. This last side effect may deprive
many uremic patients from using active vitamin D.
the most potent suppressor of the parathyroid gland
r 12,221·
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More recently calcium acetate was introduced as a
phosphate binder [22].
Aim of work
This prospective double blind crossover study was
designed to compare equivalent amounts of calcium
acetate and calcium carbonate (in terms of elemental
calcium) in the control of hyperphosphatemia in
chronic renal failure patients maintained on regular
hemodialysis.
Materials and methods
Fourty hemodialysis patients were studied. Their age
ranged between 37 and 83 years (mean ±SD=5 1.3±7).
They were 31 male and 9 female on thrice weekly
hemodialysis for 4 - 144 months using the same type
of dialyzer membrane, namely cuprophane, and the
time of dialysis session was individualized to keep Kt
/ Y> 1.2. All patients had residual creatinine clearance
of less than 5ml/ minute. A standard acetate dialysate
with a calcium concentration of 3 mEq/L was used.
All patients were clinically stable and were kept on
oral calcium carbonate in a dose of 10 m.Mol three
times/day and 0.25 ug of l-o; calcidol daily. After
obtaining consent from every patient calcium
carbonate was stopped one month before enrollment
in the study and all patients were kept on their usual
diet during the study.
Twenty cases (group I) received calcium acetate
prepared by Minapharm Pharmaceutical Co. for this
research while the other 20 patient (group II) received
calcium carbonate in the form of calcimat capsules
each of 500 mg [5 mMol] in equimolar dose (10
mMolof either t.i.d.) for one month. Cross over of
treatment for another one month was done. Patients
were advised to take the calcium treatment during
meals.
Weekly personal interviews were conducted with
every patient to assess compliance to treatment and
possible side effects.
Serum levels of calcium, ionized Calcium,
Phosphorus, alkaline phosphates, Urea, Creatinine,
Alanine transaminase (ALT), Aspartate
transaminase (AST), Total Proteins, and Albumin
were estimated before, and at the end of each
month of both calcium preparations. Ionized
calcium was analyzed using Electrostyl Analyzer
(A YL). Beckman Autoanalyzer (Synchron Clinical
System CX5) was used for other laboratory
parameters.
Statistical analysis of the obtained data was done
using the methods described by Armitage and
Berry, 1994. The results were tabulated and
statistically analyzed on an IBM personal computer
using microstar package software.
Results
Five patients (12.5%) did not tolerate calcium
acetate because of nausea, vomiting and upper GIT
upset. They were excluded as non-compliant
patients. Three other patients died during the
course of study. The rest of the patients (32, 16 in
each group) showed good tolerance for both
calcium acetate and calcium carbonate. The results
are summarized in tables 1,2 and Figures 1-3.
Table I. Different studied parameters before onset and after one month of calcium acetate and another month of calcium carbonate in group I
Item Onset After I month After 2 month PI 1'2 1'3
(mean ± SD) (mean ± SO) (meun ± SD)
S. calcium (mg%) 9.24j 0.99 8.44 j 0.81 9.5 j 1.45 «).(lOI so.os <0.01
S. ionized calcium (mg'*l 4.39j 0.46 4.27 j 0.37 4.71 j 0.72 >O.DS <D.OS <0.01
S. phosphorus (mg'k) 6.64j 1.37 6.33 j 2.05 6.54 j 1.26 so.os >0.05 >O.DS
S. alkaline phosphatase (lUlL) I22.9j 86.4 134.9 j 114.2 144.88 j 116.9 >0.05 sn.os >O.DS
S. urea (mg%) I65.2:J 18.7 148.6 j 25.25 159.56 j 20.98 <D.05 >O.OS >O.OS
S. creatinine (mg%) 12.4j 4.4 14.44 j 3.99 12.93 j 3.57 <0.05 so.os <O.DS
S. 101alprotein (gm%) 7.29j 0.76 7.29 j 0.69 7.32 j 0.69 so.os >0.05 >O.OS
S. albumin (gm%) 3.86:J 0.28 3.73 j 0.29 3.67 j 0.36 <0.05 «ios >O.D5
PI: Probability values in comparing the studied parameter at onset of study to its value after I month or calcium acetate.
P2: Probability values in comparing the studied parameter at onset of study to its value after I month of calcium carbonate.
P3: Probability values in comparing the studied parameter after I month of calcium acetate to its value after I month or calcium carbonate.
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Table 2. Different studied parameter, before onset and after Olie month of calcium carbonate and another month of calcium acetate in group n
Item Ol/se/ Af/er I month Af/er 2 1110/1/11 PI P2 PJ
(mean ± SD) (mean ±SD) (mean ± SD)
9.69:J 0.76 9.46:J 1.33 8.84:J 1.09 >0.05 <0.01 <0.05
4.43:J0"'4 4.49:J0.39 4.25 :J0.51 >0.05 >0.05 >0.05
6.68:J 2.13 6.38:J 1.9 5.65:J 1.77 >0.05 <0.05 <0.05
136.8 :J129.6 153.44 :J202.4 7 168.93 :J240.33 >0.05 >0.05 >0.05
155.3:J 17.8 149.88 :J20.53 152.13 :J23.999 >0.05 >0.05 >0.05
14.1 :J2.68 13.71 :J2.96 12.42:J1.39 >0.05 <0.05 >0.05
6.98:J 0.82 6.88:J 0.70 6.956:J 0.71 >0.05 >0.05 >0.05
3.78 :J0.43 3.55 :J0.42 3.51 :J0.43 <0.05 <0.05 >0.05
S. calcium (mg%)
S. ionized calcium (mg%)
S. phosphorus (mg%)
S. alkaline phosphatase (IU/L)
S. urea (mg%)
S. creatinine (mg%)
S. total protein (gm%)
S. albumin (gm%)
PI: Probability values in comparing the studied parameter at onset of study to it, value after I month of calcium carbonate.
P2: Probability values in comparing the studied parameter at onset of study LOiLSvalue after I month of calcium acetate.









DONSET .CALCIUM ACETATE o CALCIUM CARBONATE
S.IONIZED CALCIUM S. PHOSPHORUS
Fig. I. mrcct of calcium acetate v, calcium carbonate on S. calcium, ionized calcium and phosphours
S.ALKALINE PHOSPHATASE (IU/L) S.UREA(Mg%)
Fig. 2. Scrum alkaline phosphate and urea before, after calcium acetate and after calcium carbonale
A significant decrease of serum phosphorus was
observed after calcium acetate when compared to
values after calcium carbonate (5.98 ± 1.92 vs. 6.46 ±
1.59mg%, p<0.05). There is a highly signi ficant
decrease of serum total calcium after calcium acetate
when compared to values after calcium carbonate
(8.63 ± 0.96 vs. 9.47 ± 1.37 mg%, p < 0.00 I) and
significant decrease in serum ionized calcium after
calcium acetate when compared to values after
calcium carbonate (4.25 ± 0.44 vs. 4.6 ± 0.58 mg%,
p<O.OI). The effect of either compound on serum
alkaline phosphatase was not significant.
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ONSET .CALCIUM ACETATE OCALCIUM CARBONATE
SERUM. CREATININE (mg%) S.TOTAL PROTEIN(gm%) S.ALBUMIN(gm%)
Discussion
Fig. 3. Serum creatirune. total protein and albumin before and after calcium acetate and calcium carbonate
Hyperphospatemia is one of the distressing
consequences of C.R.F. It i~ well known that
phosphorus excretion starts to deteriorate early in the
course of C.R.F. and phosphate retention start at
creatinine clearance less than 30 ml leading to
hyperphosphatemia r 131· The rising se~'um
phosphorus lead to decrease in serum calcium,
increase PTH secretion and suppression of vitamin D
hydroxylation [10 I. Retained phosphorus decreases
serum calcium through its combination with this
calcium either in the bone or in salt tissue 1271
Increase PTH secretion in these patients is probably
due to the decrease in serum calcium, the increase of
serum phosphorus and the decrease of active vit. D1
level [271. It is well known that lowering phosphorus
level is one of the important stimulators of vitamin D
hydroxylation by the kidney [8J. Accordingly, the
increase of phosphorus level leads to ineffective
activation of vitamin D by the kidney. The skeletal
manifestation of hyperphosphaternia include the
following [16J:-
• Hyperdynamic bone disease due to hyper-
parathyroidism.
• Osteomalacia resulting from negative net calcium
balance due to vit. D. dysfunction.
Accordingly, one of the important targets will be trial
of normalization of serum phosphorus level in every
uremic patient whether before or after initiation of
dialysis treatment. This target may be achieved by
restriction of phosphorus in the diet [151. This
approach is usually difficult, non-compliant and
ineffective. Phosphorus restncuon needs severe
restriction of most of the high biological value
proteins including dairy products, meat, fish, eggs,
meat extract, etc. On the other hand, there is
increasing tendency to improve the quantity and
quality of protein ingested by the uremies to avoid
excess morbidity and mortal ity 141.
In order to control the serum phosphorus in uremic
patients on regular dialysis, li highly effective
dialyzer with big surface area and membrane with
large bore size capable of adequate clearance of
phosphorus is usually needed. However, shone
treatment times with these dialyzcrs may offset the
high clearance and thus reduce the nel removal of
phosphorus. In addition, a higher hacrnatocritc
level clue lO Erythropoict in may decrease
phosphorus clearance 171.
Accordingly an effective phosphate binder will be
needed by all uremic patients either on
conservative treatment or on regular hcrnodialy-,is.
Such a phosphate binder will allow proper nutrition
of uremies without fear of hypcrphosphatcrn ia 1141.
The first phosphate binder used in these patients
was aluminum hydroxide 1201.This compound has
many disadvantages mainly constipation and
aluminum intoxication 126, 11,251.
Calcium carbonate was thus introduced as an
alternative phosphate binder 161.Although calcium
carbonate will save the patients from aluminum
intoxication, yet it causes heart burn, constipation,
beside the risk or hypercalcemia. The increase or
calcium absorption after calcium carbonate raises
the serum calcium and thus deprives most patients
from using active vit. D 1221. It is usually needed in
these patients, not only to optimize calcium
balance, but also to suppress the hyperactive
parathyroid gland 1121.
Another phosphate binder, the calcium citrate, is
not recommended in chronic renal failure patients
as it increases the absorption of' aluminium traces
from the gut 1241.
In our study, we tried a new phosphate binder, the
calcium acetate, looking for its efficiency in
comparison to calcium carbonate together with its
effect on serurn calcium whether total or ionized. In
addition, we looked for the tolerance of patients to
this new compound.
The results of this study showed that calcium acetate
was slightly but significantly more effective as a
phosphate binder compared to calcium carbonate.
This is similar to the findings of Ring et al., 1993.
Meanwhile, the administration of equimolar doses of
calcium acetate and carbonate showed that calcium
acetate was associated with a lower level of either
serum calcium or ionized calcium. The highly
significant decrease of total serum calcium after
calcium acetate compared to values after calcium
carbonate and the significant decrease in serum
ionized calcium after calcium acetate compared to
values after calcium carbonate agree with the results
reported by others [21,17,5, 18]. On the other hand
Almirall J, et al., 1994 reported equal effect of either
compound on serum calcium. The effect of either
compound on serum alkaline phosphatase was not
signi ficant as reported by Ben Hamida. 1992. This
could be explained by:
I. Duration of treatment was too short to affect
alkaline phosphatase level as it is not a sensitive
parameter in assessing calcium-phosphorus
homeostasis in the short run.
2. The decrease in serum total calcium and ionized
calcium may neutralize the suppressing effect of
decreased serum phosphorus on parathyroid gland.
3. Patients included in this study had initially normal
serurn alkaline phosphatase ancl thus the effect of
either compound on this level will not be
appreciable.
It can be concluded that calcium acetate is a goocl
alternative to calcium carbonate as phosphate-binder
with the following advantages:
It is slightly more effective and is not associated with
hypercalcemia. It even decreases the serum calcium
level allowing any increase in the close.
A dialysate containing high calcium concentration (6-
7 mg%) can be used without fear of hypercalcemia.
The co-administration of active vitamin D will be
possible allowing more effective control of serum
calcium and PTII.
However, patients tolerate this compound less than
calcium carbonate. Five patients (12.5%) developed
nausea, vorrunng or GIT upset and discontinued the
treatment, a finding reported by Caravaca, 1991 and
Pflunz ct al., 1994.
Generally, long-term usc of this compound is
necessary to confirm the speculated advantages of this
compound on bone metabolism in uremic patients.
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